BACKGROUND:Niacin has multiple lipoprotein effects that may provide cardiovascular benefit when added to statin monotherapy. METHODS: In this randomized, placebo-controlled trial (n = 75) of magnetic resonance imaging of carotid atherosclerosis, we performed a secondary comparison of combination niacin-statin (simvastatin 20 mg/Niacin-ER 2G [S20/N]) to monotherapy with moderate (20 mg [S20]) and high-dose (80 mg [S80]) simvastatin on lipids, apolipoproteins (apo), low density lipoprotein (LDL) and high density lipoprotein (HDL) particle subclasses, and inflammatory markers. RESULTS: At baseline, average age was 71, 72% were male, 62.5% used statins, and average LDL-cholesterol was 111 mg/dL. At 12 months, S20/N, compared to S80, significantly reduced apoB (-36.6% vs -11.9%; P = .05) and lipoprotein(a) (-18% vs +3.5%; P = .001) and had at least an equivalent effect on LDL-cholesterol (-39.3% vs -24.3%; P = .24). The combination reduced the proportion of subjects with atherogenic LDL pattern-B (50% to 11.5%) compared to S80 (56% to 56%) (P = .01). Despite increases in plasma free fatty acids (+62.4%; F = 5.65, P = .005 vs S20 and S80), plasma triglycerides (-29.4%; F = 6.88, P = .002 vs S20 and S80), and very-low-density lipoprotein (-44.2%; F = 7.94, P < .001 vs S20 and S80), levels were reduced by S20/N. S20/N increased HDL-cholesterol levels (+18.1%) as compared to S20 (0%) and S80 (+5.9%) (P < .001 vs both statin arms), largely due to an increase in HDL particle size (+4.6%; P = .01 vs both statin arms). CONCLUSIONS: We demonstrate that full-dose niacin/moderate-dose simvastatin combination has sustained benefits on atherogenic apoB lipoproteins, at least comparable to high-dose simvastatin, while also raising HDL-cholesterol. Results of large clinical trials will inform whether niacin-statin combinations reduce cardiovascular disease events.
RCT Entities:
BACKGROUND:Niacin has multiple lipoprotein effects that may provide cardiovascular benefit when added to statin monotherapy. METHODS: In this randomized, placebo-controlled trial (n = 75) of magnetic resonance imaging of carotid atherosclerosis, we performed a secondary comparison of combination niacin-statin (simvastatin 20 mg/Niacin-ER 2G [S20/N]) to monotherapy with moderate (20 mg [S20]) and high-dose (80 mg [S80]) simvastatin on lipids, apolipoproteins (apo), low density lipoprotein (LDL) and high density lipoprotein (HDL) particle subclasses, and inflammatory markers. RESULTS: At baseline, average age was 71, 72% were male, 62.5% used statins, and average LDL-cholesterol was 111 mg/dL. At 12 months, S20/N, compared to S80, significantly reduced apoB (-36.6% vs -11.9%; P = .05) and lipoprotein(a) (-18% vs +3.5%; P = .001) and had at least an equivalent effect on LDL-cholesterol (-39.3% vs -24.3%; P = .24). The combination reduced the proportion of subjects with atherogenic LDL pattern-B (50% to 11.5%) compared to S80 (56% to 56%) (P = .01). Despite increases in plasma free fatty acids (+62.4%; F = 5.65, P = .005 vs S20 and S80), plasma triglycerides (-29.4%; F = 6.88, P = .002 vs S20 and S80), and very-low-density lipoprotein (-44.2%; F = 7.94, P < .001 vs S20 and S80), levels were reduced by S20/N. S20/N increased HDL-cholesterol levels (+18.1%) as compared to S20 (0%) and S80 (+5.9%) (P < .001 vs both statin arms), largely due to an increase in HDL particle size (+4.6%; P = .01 vs both statin arms). CONCLUSIONS: We demonstrate that full-dose niacin/moderate-dose simvastatin combination has sustained benefits on atherogenic apoB lipoproteins, at least comparable to high-dose simvastatin, while also raising HDL-cholesterol. Results of large clinical trials will inform whether niacin-statin combinations reduce cardiovascular disease events.
Authors: X Q Zhao; C Yuan; T S Hatsukami; E H Frechette; X J Kang; K R Maravilla; B G Brown Journal: Arterioscler Thromb Vasc Biol Date: 2001-10 Impact factor: 8.311
Authors: Steven E Nissen; Jean-Claude Tardif; Stephen J Nicholls; James H Revkin; Charles L Shear; William T Duggan; Witold Ruzyllo; William B Bachinsky; Gabriel P Lasala; Gregory P Lasala; E Murat Tuzcu Journal: N Engl J Med Date: 2007-03-26 Impact factor: 91.245
Authors: Lewis Kuller; Alice Arnold; Russell Tracy; James Otvos; Greg Burke; Bruce Psaty; David Siscovick; David S Freedman; Richard Kronmal Journal: Arterioscler Thromb Vasc Biol Date: 2002-07-01 Impact factor: 8.311
Authors: Sorin Tunaru; Jukka Kero; Annette Schaub; Christian Wufka; Andree Blaukat; Klaus Pfeffer; Stefan Offermanns Journal: Nat Med Date: 2003-02-03 Impact factor: 53.440
Authors: Michiel L Bots; Frank L Visseren; Gregory W Evans; Ward A Riley; James H Revkin; Charles H Tegeler; Charles L Shear; William T Duggan; Ralph M Vicari; Diederick E Grobbee; John J Kastelein Journal: Lancet Date: 2007-07-14 Impact factor: 79.321
Authors: Graziella E Ronsein; Patrick M Hutchins; Daniel Isquith; Tomas Vaisar; Xue-Qiao Zhao; Jay W Heinecke Journal: Arterioscler Thromb Vasc Biol Date: 2015-12-17 Impact factor: 8.311
Authors: Stefan Schandelmaier; Matthias Briel; Ramon Saccilotto; Kelechi K Olu; Armon Arpagaus; Lars G Hemkens; Alain J Nordmann Journal: Cochrane Database Syst Rev Date: 2017-06-14
Authors: Diederik F van Wijk; Aart C Strang; Raphael Duivenvoorden; Dirk-Jan F Enklaar; Rob J van der Geest; John J P Kastelein; Eric de Groot; Erik S G Stroes; Aart J Nederveen Journal: MAGMA Date: 2013-09-18 Impact factor: 2.310
Authors: Wen Guo; Siu Wong; Jeffrey Pudney; Ravi Jasuja; Ning Hua; Lan Jiang; Andrew Miller; Paul W Hruz; James A Hamilton; Shalender Bhasin Journal: Arterioscler Thromb Vasc Biol Date: 2009-09-17 Impact factor: 8.311
Authors: Robert S Rosenson; H Bryan Brewer; Benjamin J Ansell; Philip Barter; M John Chapman; Jay W Heinecke; Anatol Kontush; Alan R Tall; Nancy R Webb Journal: Nat Rev Cardiol Date: 2015-09-01 Impact factor: 32.419